Nurix posts Q1 FY2025 net loss $56.4M; bexobrutideg gets orphan drug designation

Nurix Therapeutics, Inc.

2025-Q1 EPS reported -$0.67 revenue$18,453,000

Revenue $18.5M, up from $16.6M YoY; net loss $56.4M ($0.67/share) vs $41.5M prior year.
Cash & marketable securities $549.7M at Feb 28, 2025; down from $609.6M at Nov 30, 2024.
Earned $7M milestones in quarter; post-quarter received $15M license extension fee from Sanofi.
NX-5948 named bexobrutideg; FDA Orphan Drug for Waldenström macroglobulinemia; pivotal trials in CLL on track for 2025.
Added Roy Baynes to board and John Northcott as CCO; Sanofi exercised option to license undisclosed inflammation target.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.